Loading…
12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study
The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase. A prospective cohort stu...
Saved in:
Published in: | Frontiers in cellular and infection microbiology 2022-04, Vol.12, p.864933-864933 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c465t-d6fce729ad7ffb9d634117d1482461cb83f0975a02138f0fb0f026427822ba023 |
---|---|
cites | cdi_FETCH-LOGICAL-c465t-d6fce729ad7ffb9d634117d1482461cb83f0975a02138f0fb0f026427822ba023 |
container_end_page | 864933 |
container_issue | |
container_start_page | 864933 |
container_title | Frontiers in cellular and infection microbiology |
container_volume | 12 |
creator | Liao, Xuejiao Li, Dapeng Ma, Zhenghua Zhang, Lina Zheng, Baoqi Li, Zhiyan Li, Guobao Liu, Lei Zhang, Zheng |
description | The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase.
A prospective cohort study involved patients with COVID-19 who were admitted to Shenzhen Third People's Hospital between January 11, 2020, and April 27, 2020. Patients underwent liver function tests at hospitalization and at the outpatient visit at the 1-month, 3-month, 6-month, and 12-month follow-ups.
Among 461 patients, 28.4% of patients had any kind of liver function tests abnormality at admission, manifested as elevated ALT (13.0%), AST (17.6%), and GGT (15.8%) levels. The trajectory analysis indicated a marked improvement in liver function after discharge, with any kind of liver function test abnormalities of 25.1% at 1 month, 13.2% at 3 months, 16.7% at 6 months, and 13.2% at 12 months after discharge. Persistent liver function abnormalities were observed in patients with pre-existing conditions during follow-up. A significantly higher prevalence of ultrasound determined fatty liver disease was found in those patients with more frequent LFT abnormalities at follow-up.
In this study of patients with COVID-19, liver damage in COVID-19 was usually temporary and could return to normal at the end of the 12-month follow-up. |
doi_str_mv | 10.3389/fcimb.2022.864933 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_93eca3a7445e4189b5f65b8c074b35ec</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_93eca3a7445e4189b5f65b8c074b35ec</doaj_id><sourcerecordid>2658649669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-d6fce729ad7ffb9d634117d1482461cb83f0975a02138f0fb0f026427822ba023</originalsourceid><addsrcrecordid>eNpVkk1v2yAYx61p01pl_QC7TBx3ccabMewwKXLXLVKmRmq3HRHG4FDZJgMcqbd99JGmq1ou8Lz9gOf5F8V7BJeEcPHJaje2SwwxXnJGBSGvinOMSVViwfnrZ-ez4iLGO5hXDTEX5G1xRqpcUBN8XvxFuPzhp7QDWx9Teemi3qnQG7BxBxPA1Tzp5PwEbk1MYNVOPoxqcMmZCFajn3qwVdmYUgS_XYY017_WlyUSn8EK3LipH0zZ5GgmbYOPe5NhBwMav_MhgZs0d_fvijdWDdFcPO6L4ufV19vme7m5_rZuVptSU1alsmNWmxoL1dXWtqJjhCJUd4hyTBnSLScWirpSECPCLbQttBAzimuOcZu9ZFGsT9zOqzu5D25U4V565eSDw4deqpCcHowUxGhFVE1pZSjioq0sq1quYU1bUhmdWV9OrP3cjqbT-YdBDS-gLyOT28neH6SAlAlCM-DjIyD4P3NurRxz480wqMn4OUrMquNMWU5eFOiUqnMDYzD26RoE5VEI8kEI8igEeRJCrvnw_H1PFf_HTv4BmTOvgQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2658649669</pqid></control><display><type>article</type><title>12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study</title><source>PubMed Central</source><creator>Liao, Xuejiao ; Li, Dapeng ; Ma, Zhenghua ; Zhang, Lina ; Zheng, Baoqi ; Li, Zhiyan ; Li, Guobao ; Liu, Lei ; Zhang, Zheng</creator><creatorcontrib>Liao, Xuejiao ; Li, Dapeng ; Ma, Zhenghua ; Zhang, Lina ; Zheng, Baoqi ; Li, Zhiyan ; Li, Guobao ; Liu, Lei ; Zhang, Zheng</creatorcontrib><description>The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase.
A prospective cohort study involved patients with COVID-19 who were admitted to Shenzhen Third People's Hospital between January 11, 2020, and April 27, 2020. Patients underwent liver function tests at hospitalization and at the outpatient visit at the 1-month, 3-month, 6-month, and 12-month follow-ups.
Among 461 patients, 28.4% of patients had any kind of liver function tests abnormality at admission, manifested as elevated ALT (13.0%), AST (17.6%), and GGT (15.8%) levels. The trajectory analysis indicated a marked improvement in liver function after discharge, with any kind of liver function test abnormalities of 25.1% at 1 month, 13.2% at 3 months, 16.7% at 6 months, and 13.2% at 12 months after discharge. Persistent liver function abnormalities were observed in patients with pre-existing conditions during follow-up. A significantly higher prevalence of ultrasound determined fatty liver disease was found in those patients with more frequent LFT abnormalities at follow-up.
In this study of patients with COVID-19, liver damage in COVID-19 was usually temporary and could return to normal at the end of the 12-month follow-up.</description><identifier>ISSN: 2235-2988</identifier><identifier>EISSN: 2235-2988</identifier><identifier>DOI: 10.3389/fcimb.2022.864933</identifier><identifier>PMID: 35493732</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Aftercare ; alanine aminotransferase (ALT) ; albumin ; aspartate aminotransferase (AST) ; Cellular and Infection Microbiology ; COVID-19 ; gamma-glutamyltransferase (GGT) ; Humans ; Liver Diseases ; Liver Function Tests ; Patient Discharge ; Prospective Studies ; SARS-CoV-2</subject><ispartof>Frontiers in cellular and infection microbiology, 2022-04, Vol.12, p.864933-864933</ispartof><rights>Copyright © 2022 Liao, Li, Ma, Zhang, Zheng, Li, Li, Liu and Zhang.</rights><rights>Copyright © 2022 Liao, Li, Ma, Zhang, Zheng, Li, Li, Liu and Zhang 2022 Liao, Li, Ma, Zhang, Zheng, Li, Li, Liu and Zhang</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-d6fce729ad7ffb9d634117d1482461cb83f0975a02138f0fb0f026427822ba023</citedby><cites>FETCH-LOGICAL-c465t-d6fce729ad7ffb9d634117d1482461cb83f0975a02138f0fb0f026427822ba023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046934/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046934/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35493732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liao, Xuejiao</creatorcontrib><creatorcontrib>Li, Dapeng</creatorcontrib><creatorcontrib>Ma, Zhenghua</creatorcontrib><creatorcontrib>Zhang, Lina</creatorcontrib><creatorcontrib>Zheng, Baoqi</creatorcontrib><creatorcontrib>Li, Zhiyan</creatorcontrib><creatorcontrib>Li, Guobao</creatorcontrib><creatorcontrib>Liu, Lei</creatorcontrib><creatorcontrib>Zhang, Zheng</creatorcontrib><title>12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study</title><title>Frontiers in cellular and infection microbiology</title><addtitle>Front Cell Infect Microbiol</addtitle><description>The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase.
A prospective cohort study involved patients with COVID-19 who were admitted to Shenzhen Third People's Hospital between January 11, 2020, and April 27, 2020. Patients underwent liver function tests at hospitalization and at the outpatient visit at the 1-month, 3-month, 6-month, and 12-month follow-ups.
Among 461 patients, 28.4% of patients had any kind of liver function tests abnormality at admission, manifested as elevated ALT (13.0%), AST (17.6%), and GGT (15.8%) levels. The trajectory analysis indicated a marked improvement in liver function after discharge, with any kind of liver function test abnormalities of 25.1% at 1 month, 13.2% at 3 months, 16.7% at 6 months, and 13.2% at 12 months after discharge. Persistent liver function abnormalities were observed in patients with pre-existing conditions during follow-up. A significantly higher prevalence of ultrasound determined fatty liver disease was found in those patients with more frequent LFT abnormalities at follow-up.
In this study of patients with COVID-19, liver damage in COVID-19 was usually temporary and could return to normal at the end of the 12-month follow-up.</description><subject>Aftercare</subject><subject>alanine aminotransferase (ALT)</subject><subject>albumin</subject><subject>aspartate aminotransferase (AST)</subject><subject>Cellular and Infection Microbiology</subject><subject>COVID-19</subject><subject>gamma-glutamyltransferase (GGT)</subject><subject>Humans</subject><subject>Liver Diseases</subject><subject>Liver Function Tests</subject><subject>Patient Discharge</subject><subject>Prospective Studies</subject><subject>SARS-CoV-2</subject><issn>2235-2988</issn><issn>2235-2988</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkk1v2yAYx61p01pl_QC7TBx3ccabMewwKXLXLVKmRmq3HRHG4FDZJgMcqbd99JGmq1ou8Lz9gOf5F8V7BJeEcPHJaje2SwwxXnJGBSGvinOMSVViwfnrZ-ez4iLGO5hXDTEX5G1xRqpcUBN8XvxFuPzhp7QDWx9Teemi3qnQG7BxBxPA1Tzp5PwEbk1MYNVOPoxqcMmZCFajn3qwVdmYUgS_XYY017_WlyUSn8EK3LipH0zZ5GgmbYOPe5NhBwMav_MhgZs0d_fvijdWDdFcPO6L4ufV19vme7m5_rZuVptSU1alsmNWmxoL1dXWtqJjhCJUd4hyTBnSLScWirpSECPCLbQttBAzimuOcZu9ZFGsT9zOqzu5D25U4V565eSDw4deqpCcHowUxGhFVE1pZSjioq0sq1quYU1bUhmdWV9OrP3cjqbT-YdBDS-gLyOT28neH6SAlAlCM-DjIyD4P3NurRxz480wqMn4OUrMquNMWU5eFOiUqnMDYzD26RoE5VEI8kEI8igEeRJCrvnw_H1PFf_HTv4BmTOvgQ</recordid><startdate>20220414</startdate><enddate>20220414</enddate><creator>Liao, Xuejiao</creator><creator>Li, Dapeng</creator><creator>Ma, Zhenghua</creator><creator>Zhang, Lina</creator><creator>Zheng, Baoqi</creator><creator>Li, Zhiyan</creator><creator>Li, Guobao</creator><creator>Liu, Lei</creator><creator>Zhang, Zheng</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220414</creationdate><title>12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study</title><author>Liao, Xuejiao ; Li, Dapeng ; Ma, Zhenghua ; Zhang, Lina ; Zheng, Baoqi ; Li, Zhiyan ; Li, Guobao ; Liu, Lei ; Zhang, Zheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-d6fce729ad7ffb9d634117d1482461cb83f0975a02138f0fb0f026427822ba023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aftercare</topic><topic>alanine aminotransferase (ALT)</topic><topic>albumin</topic><topic>aspartate aminotransferase (AST)</topic><topic>Cellular and Infection Microbiology</topic><topic>COVID-19</topic><topic>gamma-glutamyltransferase (GGT)</topic><topic>Humans</topic><topic>Liver Diseases</topic><topic>Liver Function Tests</topic><topic>Patient Discharge</topic><topic>Prospective Studies</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liao, Xuejiao</creatorcontrib><creatorcontrib>Li, Dapeng</creatorcontrib><creatorcontrib>Ma, Zhenghua</creatorcontrib><creatorcontrib>Zhang, Lina</creatorcontrib><creatorcontrib>Zheng, Baoqi</creatorcontrib><creatorcontrib>Li, Zhiyan</creatorcontrib><creatorcontrib>Li, Guobao</creatorcontrib><creatorcontrib>Liu, Lei</creatorcontrib><creatorcontrib>Zhang, Zheng</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in cellular and infection microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liao, Xuejiao</au><au>Li, Dapeng</au><au>Ma, Zhenghua</au><au>Zhang, Lina</au><au>Zheng, Baoqi</au><au>Li, Zhiyan</au><au>Li, Guobao</au><au>Liu, Lei</au><au>Zhang, Zheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study</atitle><jtitle>Frontiers in cellular and infection microbiology</jtitle><addtitle>Front Cell Infect Microbiol</addtitle><date>2022-04-14</date><risdate>2022</risdate><volume>12</volume><spage>864933</spage><epage>864933</epage><pages>864933-864933</pages><issn>2235-2988</issn><eissn>2235-2988</eissn><abstract>The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase.
A prospective cohort study involved patients with COVID-19 who were admitted to Shenzhen Third People's Hospital between January 11, 2020, and April 27, 2020. Patients underwent liver function tests at hospitalization and at the outpatient visit at the 1-month, 3-month, 6-month, and 12-month follow-ups.
Among 461 patients, 28.4% of patients had any kind of liver function tests abnormality at admission, manifested as elevated ALT (13.0%), AST (17.6%), and GGT (15.8%) levels. The trajectory analysis indicated a marked improvement in liver function after discharge, with any kind of liver function test abnormalities of 25.1% at 1 month, 13.2% at 3 months, 16.7% at 6 months, and 13.2% at 12 months after discharge. Persistent liver function abnormalities were observed in patients with pre-existing conditions during follow-up. A significantly higher prevalence of ultrasound determined fatty liver disease was found in those patients with more frequent LFT abnormalities at follow-up.
In this study of patients with COVID-19, liver damage in COVID-19 was usually temporary and could return to normal at the end of the 12-month follow-up.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>35493732</pmid><doi>10.3389/fcimb.2022.864933</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2235-2988 |
ispartof | Frontiers in cellular and infection microbiology, 2022-04, Vol.12, p.864933-864933 |
issn | 2235-2988 2235-2988 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_93eca3a7445e4189b5f65b8c074b35ec |
source | PubMed Central |
subjects | Aftercare alanine aminotransferase (ALT) albumin aspartate aminotransferase (AST) Cellular and Infection Microbiology COVID-19 gamma-glutamyltransferase (GGT) Humans Liver Diseases Liver Function Tests Patient Discharge Prospective Studies SARS-CoV-2 |
title | 12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A47%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=12-Month%20Post-Discharge%20Liver%20Function%20Test%20Abnormalities%20Among%20Patients%20With%20COVID-19:%20A%20Single-Center%20Prospective%20Cohort%20Study&rft.jtitle=Frontiers%20in%20cellular%20and%20infection%20microbiology&rft.au=Liao,%20Xuejiao&rft.date=2022-04-14&rft.volume=12&rft.spage=864933&rft.epage=864933&rft.pages=864933-864933&rft.issn=2235-2988&rft.eissn=2235-2988&rft_id=info:doi/10.3389/fcimb.2022.864933&rft_dat=%3Cproquest_doaj_%3E2658649669%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-d6fce729ad7ffb9d634117d1482461cb83f0975a02138f0fb0f026427822ba023%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2658649669&rft_id=info:pmid/35493732&rfr_iscdi=true |